Table 2. Assessment of the quality of evidence of the eligible studies.

Study	Study design	Study size	Method of measuring exposure	Method of measuring outcome	Analysis with adjustment	Total
Abbas et al., 2022 [27]	0	1	0	2	0	3/10
Aksak et al., 2022 [28]	0	2	2	2	2	8/10
Al-Alami et al., 2022 [29]	0	2	1	1	1	5/10
Al-Bashiti et al., 2022 [30]	0	2	2	2	0	6/10
Azzawi and Abdulrahman, 2022 [31]	0	1	0	2	0	3/10
Best et al, 2021 [32]	1	1	2	2	0	6/10
Camici et al., 2021 [33]	0	0	2	2	1	5/10
Cinislioglu et al., 2022 [34]	1	2	2	2	1	8/10
Dipankar et al., 2022 [35]	1	0	2	2	01	6/10
Enikeev et al., 2022 [36]	1	1	2	2	01	7/10
Erbay et al., 2021 [37]	0	1	2	02	0	5/10
Falahieh et al., 2021 [38]	1	0	2	2	0	5/10
Gacci et al., 2021 [39]	0	0	2	2	1	5/10
Gul et al., 2021 [40]	0	0	1	1	2	4/10
Guo et al., 2021 [41]	1	1	2	2	1	7/10
Hadisi et al., 2022 [42]	0	1	2	2	1	6/10
Hamarat et al., 2022 [43]	1	0	2	2	1	6/10
Holtmann et al., 2020 [44]	0	0	2	2	1	5/10
Hu et al., 2022 [45]	1	1	2	2	1	7/10
Kadihasanoglu et al., 2021 [46]	1	2	2	2	1	8/10
Karkin & Gürlen, 2022 [47]	0	2	2	2	1	7/10
Koç and Keseroğlu, 2021 [48]	0	0	2	2	0	4/10
Kumar et al., 2023 [49]	1	0	2	2	0	5/10
Li et al., 2020 [50]	0	0	2	2	0	4/10
Livingstone et al., 2022 [51]	0	1	2	2	1	6/10
Ma et al., 2021 [52]	1	2	2	2	1	8/10
Maleki and Tartibian, 2021 [53]	1	2	2	2	1	8/10
Okçelik, 2020 [54]	1	0	2	2	2	7/10
Paoli et al., 2023 [55]	0	2	2	2	1	7/10
Pazir et al., 2021 [56]	0	0	2	2	0	4/10
Piroozmanesh et al., 2021 [57]	0	1	2	2	1	6/10
Rafiee and Tabei, 2021 [58]	2	1	2	2	0	7/10
Ruan et al., 2021 [59]	0	2	2	2	1	7/10
Salonia et al., 2021 [60]	0	2	2	2	0	6/10
Salonia1 et al., 2022 [61]	1	2	2	2	2	9/10
Sunnu et al., 2022 [62]	1	0	2	2	0	5/10
Temiz et al., 2020 [63]	2	0	2	2	1	7/10
Vahidi et al., 2022 [64]	0	0	2	2	0	4/10
Wang et al., 2022 [65]	0	0	2	2	1	5/10
Xu et al., 2021 [66]	0	1	2	2	2	7/10